GGrantIndex
← Leaderboards

David C Linehan

University Of Rochester

$5,269,651
Attributed
$6,072,551
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,072,551 · 9

By mechanism

R01$5,196,732 · 2
K08$624,435 · 1
P30$211,524 · 2
P41$39,860 · 4

Top collaborators

Most similar at University Of Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsClinical TrialsImmunePancreatic Ductal AdenocarcinomaCessation Of LifeMalignant Neoplasm Of PancreasMyeloid CellsPeripheral BloodTumor MicroenvironmentTumorMediatingEffective TherapyCancer EtiologyPre-Clinical ModelExcisionMalignant NeoplasmsOperative Surgical ProceduresBeta-ChemokinesMonocyteInflammatoryMouse ModelNeoplastic CellBone MarrowBlood

Grant awards (27)

Clinical Protocol and Data Management$135,585
P30 · FY2025 · CA · contact PI
Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic Cancer$83,487
R01 · FY2025 · CA
Protocol Review and Monitoring System$75,939
P30 · FY2025 · CA · contact PI
Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic Cancer$490,237
R01 · FY2024 · CA
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity$334,305
R01 · FY2023 · CA · contact PI
Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic Cancer$516,038
R01 · FY2022 · CA
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity$338,099
R01 · FY2022 · CA · contact PI
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity$522,237
R01 · FY2021 · CA · contact PI
Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic Cancer$516,038
R01 · FY2021 · CA
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity$351,098
R01 · FY2020 · CA · contact PI
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity$118,067
R01 · FY2020 · CA · contact PI
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity$349,385
R01 · FY2019 · CA · contact PI
CCR2 BLOCKADE IN HUMAN PANCREATIC CANCER$319,377
R01 · FY2017 · CA · contact PI
CCR2 BLOCKADE IN HUMAN PANCREATIC CANCER$318,513
R01 · FY2016 · CA · contact PI
CCR2 BLOCKADE IN HUMAN PANCREATIC CANCER$318,513
R01 · FY2015 · CA · contact PI
CCR2 BLOCKADE IN HUMAN PANCREATIC CANCER$305,938
R01 · FY2014 · CA · contact PI
CCR2 BLOCKADE IN HUMAN PANCREATIC CANCER$315,400
R01 · FY2013 · CA · contact PI
IDENTIFICATION OF PROGNOSTIC BIOMARKERS IN PANCREAS CANCER$6,075
P41 · FY2011 · RR · contact PI
IDENTIFICATION OF PROGNOSTIC BIOMARKERS IN PANCREAS CANCER$14,575
P41 · FY2010 · RR · contact PI
IDENTIFICATION OF PROGNOSTIC BIOMARKERS IN PANCREAS CANCER$5,825
P41 · FY2009 · RR · contact PI
IDENTIFICATION OF PROGNOSTIC BIOMARKERS IN PANCREAS CANCER$13,385
P41 · FY2008 · RR · contact PI
Multivalent Dendritic Cell Vaccine in Pancreas Cancer$62,444
K08 · FY2006 · CA · contact PI
Multivalent Dendritic Cell Vaccine in Pancreas Cancer$124,887
K08 · FY2005 · CA
Multivalent Dendritic Cell Vaccine in Pancreas Cancer$124,887
K08 · FY2004 · CA
Multivalent Dendritic Cell Vaccine in Pancreas Cancer$124,887
K08 · FY2003 · CA
Multivalent Dendritic Cell Vaccine in Pancreas Cancer$62,443
K08 · FY2002 · CA
Multivalent Dendritic Cell Vaccine in Pancreas Cancer$124,887
K08 · FY2001 · CA